Haemorrhagic gastritis and bleeding following rofecoxib administration [5]

Clinical and Experimental Rheumatology

Volumn 23, Issue 5, 2005, Pages 727-728

  Tuccori, M ^a   Salvetti, A ^b   Martini, G ^b   Blandizzi, C ^a   Giustini, S E ^b   Del Tacca, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Italian Society of General Medicine SIMG   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

AGED; ANALGESIA; CASE REPORT; DISEASE SEVERITY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMORRHAGIC GASTRITIS; HUMAN; KNEE OSTEOARTHRITIS; LETTER; LOW BACK PAIN; OSTEOARTHRITIS; PATIENT REFERRAL; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; ANTI-ULCER AGENTS; CYCLOOXYGENASE INHIBITORS; FEMALE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROSCOPY; HUMANS; LACTONES; OMEPRAZOLE; OSTEOARTHRITIS; SULFONES; TREATMENT OUTCOME;

EID: 24944437256     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. CRYER B: The role of cylooxygenase selective inhibitors in the gastrointestinal tract. Curr Gastroenterol Rep 2003; 5: 453-8.
2. NARANJO CA, BUSTO U, SELLERS EM, SANDOR P, RUIZ I, ROBERTS EA: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
3. AALYKKE C, LAURITSEN K: Epidemiology of NSAID-related gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 2001: 705-22.
4. LAINE L: Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120: 594-606.
5. LAPORTE JR, IBANEZ L, VIDAL X, VENDRELL L, LEONE R: Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004; 27: 411-20.
6. LAYTON D, HEELEY E, HUGHES K, SHAKIR SA: Comparison of the incidence rate of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data. Rheumatology (Oxford) 2003; 42: 622-31.
7. MacDONALD TM, MORANT SV, GOLDSTEIN JL, BURKE TA, PETTITT D: Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs and older, non-specific non-steroidal anti-inflammatory drugs. Gut 2003; 52: 1265-70.
8. SCHNITZER TJ: Update of ACR guidelines for osteoarthritis: role of coxibs. J Pain Symptom Manag 2002; 23 (Suppl. 4): S24-S30.
9. TO KF, CHAN FK, CHENG AS, LEE TL, NG YP, SUNG JJ: Up-regulation of cyclooxygenase-1 and -2 in human gastric ulcer. Aliment Pharmacol Ther 2001; 15: 25-34.
10. HALTER F, TARNAWSKI AS, SCHMASSMANN A, PESKAR BM: Cyclooxygenase-2 implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 2001; 49: 443-53.